🇺🇸 FDA
Pipeline program

ETC-1002

1002-006

Phase 3 small_molecule completed

Quick answer

ETC-1002 for Hypercholesterolemia is a Phase 3 program (small_molecule) at Esperion Therapeutics with 6 ClinicalTrials.gov record(s).

Program details

Company
Esperion Therapeutics
Indication
Hypercholesterolemia
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials